The Federal Trade Commission (“FTC”) released its second interim report on Jan. 14, 2025, accusing pharmacy benefit managers (PBMs) of marking up the prices of specialty generic drugs. FTC’s report ...
The Health Care Benefits segment includes Aetna and other health insurance businesses. CVS acquired Aetna in 2017. In 2023, ...
Zydus Lifesciences announced that it has entered into an agreement with CVS Caremark, a CVS Health (CVS) company, to add Zituvio, Zituvimet and ...
Hosted on MSN1d
What You Need To Know Ahead of CVS Health's Earnings ReleaseWith a market cap of $64.8 billion, CVS Health Corporation (CVS) is a leading pharmacy innovation company providing a wide ...
Zydus enters agreement with CVS Caremark to add Zituvio, Zituvimet and Zituvimet XR to its template formulary: Our Bureau, Mumbai Tuesday, January 7, 2025, 17:15 Hrs [IST] Zydus L ...
CVS’ efforts to reform how its pharmacies are paid have reached a significant milestone that should stabilize flagging ...
CVS Caremark will add Zydus' ZituvioTM and combination products to its template formulary starting January 1, 2025 ...
Wells Fargo analyst Stephen Baxter maintained a Buy rating on CVS Health (CVS – Research Report) on January 10 and set a price target of ...
Zydus Lifesciences has partnered with CVS Caremark to add its diabetes medications, Zituvio, Zituvimet, and Zituvimet XR, to ...
Three major drug middlemenneedlessly marked up generic drugs for cancer, HIV, and multiple sclerosis to generate $7.3 billion ...
Zacks.com on MSN1d
CVS Health Corporation (CVS) is Attracting Investor Attention: Here is What You Should KnowCVS Health (CVS) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback